Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Wang X, et al. Among authors: jiang kk. JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370. JAMA. 2021. PMID: 33300950 Free PMC article. Clinical Trial.
Pretreatment anti-Mullerian hormone-based nomogram predicts menstruation status after chemotherapy for premenopausal women with hormone receptor-positive early breast cancer.
Xue C, Wei W, Sun P, Zheng W, Diao X, Xu F, Huang J, An X, Xia W, Hong R, Jiang K, Huang R, Yuan Z, Wang S, Li A, Zou R, Shi Y. Xue C, et al. Breast Cancer Res Treat. 2019 Feb;173(3):619-628. doi: 10.1007/s10549-018-4997-2. Epub 2018 Nov 3. Breast Cancer Res Treat. 2019. PMID: 30392113
Safety, tolerability, and pharmacokinetics of BAT8001 in patients with HER2-positive breast cancer: An open-label, dose-escalation, phase I study.
Hong R, Xia W, Wang L, Lee K, Lu Q, Jiang K, Li S, Yu J, Wei J, Tang W, Zhou D, An X, Huang J, Xue C, Bi X, Shi Y, Yuan Z, Xu F, Wang S. Hong R, et al. Cancer Commun (Lond). 2021 Feb;41(2):171-182. doi: 10.1002/cac2.12135. Epub 2021 Feb 2. Cancer Commun (Lond). 2021. PMID: 33528890 Free PMC article. Clinical Trial.
24 results